Bitopertin Delivers 3.5 Years of Sun Tolerance in EPP Trial Patient
An EPP patient reports 3.5 years of sun tolerance on Phase 3 bitopertin, calling it easier and more effective than dersimelagon after his first gear-free beach visit.
Topic
Heme Biosynthesis
Topic